Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing with the launch of Quest Mobile.

Quest Diagnostics' (DGX) base business growth reflects the company's ongoing efforts to partner with health plans, hospitals and physicians amid a continued return to care.

Quest Diagnostics (DGX) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.36 per share a year ago.

Quest Diagnostics Inc. DGX, -1.84% said Tuesday its third-quarter profit dropped by 12.2% to $225 million, or $1.96 a share, from $256 million, or $2.17 a share, in the year-ago quarter. Adjusted t...

Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business.

Quest Diagnostics' (DGX) recent acquisition of New York-Presbyterian's outreach assets adds to volume growth within Physician Lab Services.

Quest Diagnostics (DGX) latest deal will boost dialysis laboratory testing and reduce the laboratory costs of dialysis programs for ESRD patients.

SECAUCUS, N.J. , Oct. 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarte...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the lat...

Quest Diagnostics (DGX) and Americares will provide 10 clinics with no-cost diagnostic services for a year to help patients manage chronic disease.

SECAUCUS, N.J. , Sept. 8, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that Sam Samad, Executive Vice ...

Quest Diagnostics (DGX) achieves breakthrough designation for AAVrh74 ELISA and expands collaboration with Sarepta Therapeutics.

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

Quest Diagnostics has a strong Q2 with a slight beat on EPS and revenue. Quest's base business appears to be recovering from the pandemic and pulled in $2.30B in revenue. Despite fading COVID-relat...

Biogen and Eli Lilly both have treatments to help reduce cognitive decline in Alzheimer's patients. But the key to their effectiveness is in treating people who have the disease in its early stages.